Stay updated with breaking news from Nasdaq Cbay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) have been given a consensus recommendation of “Buy” by the ten ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy […]
William Blair started coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) in a research note released on Wednesday morning, MarketBeat reports. The brokerage issued an outperform rating on the biopharmaceutical company’s stock. William Blair also issued estimates for CymaBay Therapeutics’ Q1 2023 earnings at ($0.28) EPS, Q2 2023 earnings at ($0.28) EPS, Q3 […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 7,650,000 shares, an increase of 54.9% from the February 28th total of 4,940,000 shares. Based on an average daily volume of 1,640,000 shares, the short-interest ratio is presently 4.7 days. […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 7,650,000 shares, an increase of 54.9% from the February 28th total of 4,940,000 shares. Based on an average trading volume of 1,640,000 shares, the days-to-cover ratio is […]
Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they co